Skip to main content

Research News

Crack GPAT — Prepare for GPAT Online 
  • Detecting disease with only a single molecule

    UC Riverside scientists have developed a nanopore-based tool that could help diagnose illnesses much faster and with greater precision than current tests allow, by capturing signals from individual molecules.

  • HKUMed confirms clozapine safety with first big-data evidence on rare blood cancer cases
    An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong has conducted the world’s first analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer.
  • New scan method unveils lung function secrets

    The scan method has enabled the team, led by researchers at Newcastle University, UK, to see how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant.

  • U of T researchers develop tool to fast-track measurement of protein interactions for drug discovery

    A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that revolutionizes the study of protein-protein interactions by simplifying detection while improving measurement accuracy.

  • New Drug to Prevent Migraine May Start Working Right Away
    A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. The study looked at the drug atogepant, which is a calcitonin gene-related peptide CGRP receptor antagonist taken by mouth.
  • Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

    Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important for the treatment of heart failure. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.

  • New drug shows promise against Duchenne muscular dystrophy
    A novel drug holds promise for treating Duchenne muscular dystrophy, a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an experimental compound called K884 can boost the natural repair abilities of muscle stem cells. Current treatments can slow muscle damage, but don’t address the root problem.
  • UW researchers find previously unknown links between microbial bile acids and the risk of colon cancer

    In many ways, that relationship revolves around a specific protein called the farnesoid X receptor, or FXR, which helps maintain a healthy gut through its intimate relationship with bile acids. FXR controls the production of bile acids in the liver, but it also responds in different ways to the presence of various bile acids that microbes have modified.  

  • Unlocking the Brain : Peptide-Guided Nanoparticles Deliver mRNA to Neurons
    Penn Engineers have modified lipid nanoparticles the revolutionary technology behind the COVID-19 mRNA vaccines to not only cross the blood-brain barrier but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer’s and Parkinsons.
  • Activating the hidden pharmaceutical potential of bacteria

    Researchers develop a new genetic method for the production of new active ingredients in bacteria

Subscribe to Research News